SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Raymond James 42nd Annual Institutional Investors Conference on Wednesday, March 3, 2021 at 12:30 PM ET.
The presentation will be available through the Raymond James conference portal and an archived webcast will also be accessible in the investor section of 89bio’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com
COCONUT GROVE, Fla., April 28, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or…
NEW YORK, April 28, 2025 /PRNewswire/ -- Muse Health is proud to announce its new…
Reality Star Joan Vassos, "Star Trek" Team, Days of our Lives' Martha Madison & Cast Members…
A new report from global research and advisory firm Info-Tech Research Group highlights the top…
In a new SHIN-NY collaboration, Hixny has made it easy for providers across the stateto screen patients for HRSN and query the state's controlled substance database. ALBANY, N.Y., April 28, 2025 /PRNewswire/ -- Hixny,…
PACS fuels faster, more precise diagnosis and patient triaging for busy healthcare providers to assist…